

02-25-00

A

Practitioner's Docket No. MSU 4.1-458

PATENT

02/24/00

jc644 U.S. PTO

Preliminary Classification:

Proposed Class:

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand corner of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129.'" M.P.E.P. § 601, 7th ed.

jc675 U.S. PTO

09/513086

02/24/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Linda S. Mansfield, Mary G. Rossano, Alice J. Murphy and
Ruth A. Vrable

WARNING: 37 C.F.R. § 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

"(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name or names of the inventor or inventors."

For (title): VACCINE TO CONTROL EQUINE PROTOZOAL MYELOENCEPHALITIS
IN HORSES

CERTIFICATION UNDER 37 C.F.R. § 1.10*


(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this New Application Transmittal and the documents referred to as attached therein are being deposited with the United States Postal Service on this date Feb. 24, 2000, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EE488567620US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Peggy L. Casper

(type or print name of person mailing paper)



Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. § 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing 37 C.F.R. § 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(New Application Transmittal [4-1]—page 1 of 11)

1. Type of Application

This new application is for a(n)

(check one applicable item below)

- ☒ Original (nonprovisional)
☐ Design
☐ Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. § 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

WARNING: Do not use this transmittal for the filing of a provisional application.

NOTE: If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.

- ☐ Divisional.
☐ Continuation.
☐ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. §§ 119(e), 120, or 121)

NOTE: A nonprovisional application may claim an invention disclosed in one or more prior filed copending nonprovisional applications or copending international applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed copending nonprovisional application or copending international application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. § 112. Each prior application must also be:

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16; or

(iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(l) within the time period set forth in § 1.53(f).

37 C.F.R. § 1.78(a)(1).

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. §§ 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. §§ 120, 121 or 365(c). (35 U.S.C. § 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. §§ 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

(New Application Transmittal [4-1]—page 2 of 11)

WARNING: When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application **must** be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).

- ☒ The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

A. Required for filing date under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application

44 Pages of specification

10 Pages of claims

0 Sheets of drawing

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed then-new 37 C.F.R. § 1.84, see Notice of March 9, 1988 (1990 O.G. 57-62).

NOTE: "Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page . . ." 37 C.F.R. § 1.84(c).

(complete the following, if applicable)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. § 1.84(b).

☐ formal

☐ informal

B. Other Papers Enclosed

8 Pages of declaration and power of attorney

1 Pages of abstract

 Other

4. Additional papers enclosed

☐ Amendment to claims

☐ Cancel in this applications claims _____ before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)

☐ Preliminary Amendment

☒ Information Disclosure Statement (37 C.F.R. § 1.98)

☒ Form PTO-1449 (PTO/SB/08A and 08B)

☒ Citations

- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☐ Other

5. Declaration or oath (including power of attorney)

NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3).

NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4).

NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(f) is filed supplying or changing the name or names of the inventor or inventors." 37 C.F.R. § 1.41(a)(1).

☒ Enclosed

Executed by

(check all applicable boxes)

☒ inventor(s).

☐ legal representative of inventor(s).
37 C.F.R. §§ 1.42 or 1.43.

☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

☐ This is the petition required by 37 C.F.R. § 1.47 and the statement required by 37 C.F.R. § 1.47 is also attached. See item 13 below for fee.

☐ Not Enclosed.

NOTE: Where the filing is a completion in the U.S. of an International Application or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

☐ Application is made by a person authorized under 37 C.F.R. § 1.41(c) on behalf of all the above named inventor(s).

(The declaration or oath, along with the surcharge required by 37 C.F.R. § 1.16(e) can be filed subsequently).

- ☐ Showing that the filing is authorized.
(not required unless called into question. 37 C.F.R. § 1.41(d))

6. Inventorship Statement

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

- ☒ The same.

or

- ☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
☐ is submitted.
☐ will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$130.00 required by 37 C.F.R. § 1.17(k) is required to be filed with the application, or within such time as may be set by the Office. 37 C.F.R. § 1.52(d).

- ☒ English
☐ Non-English
☐ The attached translation includes a statement that the translation is accurate. 37 C.F.R. § 1.52(d).

8. Assignment

- ☒ An assignment of the invention to Board of Trustees operating
Michigan State University
301 Administration Bldg., MSU, East Lansing, MI 48824
☒ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.
☐ will follow.

NOTE: "If an assignment is submitted with a new application, send two separate letters—one for the application and one for the assignment." Notice of May 4, 1990 (1114 O.G. 77-78).

WARNING: A newly executed "CERTIFICATE UNDER 37 C.F.R. § 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.

(New Application Transmittal [4-1]—page 5 of 11)

9. Certified Copy

Certified copy(ies) of application(s)

Country	Appln. No.	Filed
Country	Appln. No.	Filed
Country	Appln. No.	Filed

from which priority is claimed

☐ is (are) attached.

☐ will follow.

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 C.F.R. § 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. § 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. § 1.16)

A. ☒ Regular application

CLAIMS AS FILED			
Number filed	Number Extra	Rate	Basic Fee 37 C.F.R. § 1.16(a) \$690.00
Total Claims (37 C.F.R. § 1.16(c))	50 - 20 = -30-	× \$ 18.00	\$ 540.00
Independent Claims (37 C.F.R. § 1.16(b))	17 - 3 = -14-	× \$ 78.00	\$ 1,092
Multiple dependent claim(s), if any (37 C.F.R. § 1.16(d))	1	+ \$260.00	\$ 260.00

☐ Amendment cancelling extra claims is enclosed.

☐ Amendment deleting multiple-dependencies is enclosed.

☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 C.F.R. § 1.16(d).

Filing Fee Calculation

\$ 2,582.00

B. ☐ Design application

(\$310.00—37 C.F.R. § 1.16(f))

Filing Fee Calculation

\$

- C. ☐ Plant application
(\$480.00—37 C.F.R. § 1.16(g))

Filing fee calculation

\$ _____

11. Small Entity Statement(s)

- ☒ Statement(s) that this is a filing by a small entity under 37 C.F.R. § 1.9 and 1.27 is (are) attached.

WARNING: "Status as a small entity must be specifically established in each application or patent in which the status is available and desired. Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. The refiling of an application under § 1.53 as a continuation, division, or continuation-in-part (including a continued prosecution application under § 1.53(d)), or the filing of a reissue application requires a new determination as to continued entitlement to small entity status for the continuing or reissue application. A nonprovisional application claiming benefit under 35 U.S.C. § 119(e), 120, 121, or 365(c) of a prior application, or a reissue application may rely on a statement filed in the prior application or in the patent if the nonprovisional application or the reissue application includes a reference to the statement in the prior application or in the patent or includes a copy of the statement in the prior application or in the patent and status as a small entity is still proper and desired. The payment of the small entity basic statutory filing fee will be treated as such a reference for purposes of this section." 37 C.F.R. § 1.28(a)(2).

WARNING: "Small entity status must not be established when the person or persons signing the . . . statement can **unequivocally** make the required self-certification." M.P.E.P., § 509.03, 6th ed., rev. 2, July 1996 (emphasis added).

(complete the following, if applicable)

- ☐ Status as a small entity was claimed in prior application

_____ / _____, filed on _____, from which benefit is being claimed for this application under:

- 35 U.S.C. § ☐ 119(e),
☐ 120,
☐ 121,
☐ 365(c),

and which status as a small entity is still proper and desired.

- ☐ A copy of the statement in the prior application is included.

Filing Fee Calculation (50% of A, B or C above)

\$ 1,291.00

NOTE: Any excess of the full fee paid will be refunded if small entity status is established and a refund request are filed within 2 months of the date of timely payment of a full fee. The two-month period is not extendable under § 1.136. 37 C.F.R. § 1.28(a).

12. Request for International-Type Search (37 C.F.R. § 1.104(d))

(complete, if applicable)

- ☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13. Fee Payment Being Made at This Time

☐ Not Enclosed

☐ No filing fee is to be paid at this time.

(This and the surcharge required by 37 C.F.R. § 1.16(e) can be paid subsequently.)

☒ Enclosed

☒ Filing fee \$ 1,291.00

☒ Recording assignment
(\$40.00; 37 C.F.R. § 1.21(h))
(See attached "COVER SHEET FOR
ASSIGNMENT ACCOMPANYING NEW
APPLICATION".) \$ 40.00

☐ Petition fee for filing by other than all the
inventors or person on behalf of the inventor
where inventor refused to sign or cannot be
reached
(\$130.00; 37 C.F.R. §§ 1.47 and 1.17(i)) \$ _____

☐ For processing an application with a
specification in
a non-English language
(\$130.00; 37 C.F.R. §§ 1.52(d) and 1.17(k)) \$ _____

☐ Processing and retention fee
(\$130.00; 37 C.F.R. §§ 1.53(d) and 1.21(l)) \$ _____

☐ Fee for international-type search report
(\$40.00; 37 C.F.R. § 1.21(e)) \$ _____

NOTE: 37 C.F.R. § 1.21(l) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 C.F.R. § 1.53(f) and this, as well as the changes to 37 C.F.R. §§ 1.53 and 1.78(a)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(l) must be paid, within 1 year from notification under § 53(f).

Total fees enclosed \$ 1,331.00

14. Method of Payment of Fees

☒ Check in the amount of \$ 1,331.00

☐ Charge Account No. _____ in the amount of
\$ _____.

A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 C.F.R. § 1.22(b).

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing, the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

- ☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 13-0610.

☒ 37 C.F.R. § 1.16(a), (f) or (g) (filing fees)

☒ 37 C.F.R. § 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☐ 37 C.F.R. § 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☒ 37 C.F.R. § 1.17(a)(1)–(5) (extension fees pursuant to § 1.136(a)).

☒ 37 C.F.R. § 1.17 (application processing fees)

NOTE: “. . . A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission.” 37 C.F.R. § 1.136(a)(3).

☐ 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. § 1.28(b) requires “Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . the issue fee. . . .” From the wording of 37 C.F.R. § 1.28(b), (a) notification of change of status must be made even if the fee is paid as “other than a small entity” and (b) no notification is required if the change is to another small entity.

(New Application Transmittal [4-1]—page 9 of 11)

16. Instructions as to Overpayment

NOTE: "... Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).

- ☒ Credit Account No. 13-0610
☐ Refund

Reg. No. 20,931

Tel. No. (517) 347-4100

Customer No. 21036



SIGNATURE OF PRACTITIONER

Ian C. McLeod

(type or print name of attorney)

2190 Commons Parkway

P.O. Address

Okemos, Michigan 48864

☒ **Incorporation by reference of added pages**

(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

- ☒ Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added 5

- ☐ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added _____

- ☐ Plus added pages deleting names of inventor(s) named in prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.

Number of pages added _____

- ☐ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added _____

- ☐ **Statement Where No Further Pages Added**

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

- ☐ This transmittal ends with this page.

**ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF
PRIOR U.S. APPLICATION(S) CLAIMED**

NOTE: See 37 C.F.R. § 1.78.

17. Relate Back

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. §§ 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. §§ 120, 121 or 365(c). (35 U.S.C. § 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. §§ 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

(complete the following, if applicable)

☒ Amend the specification by inserting, before the first line, the following sentence:**A. 35 U.S.C. § 119(e)**

NOTE: "Any nonprovisional application claiming the benefit of one or more prior filed copending provisional applications must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of series code and serial number)." 37 C.F.R. § 1.78(a)(4).

☒ "This application claims the benefit of U.S. Provisional Application(s) No(s).:**APPLICATION NO(S).:****FILING DATE**

60 / 152,193

9/2/99 "

B. 35 U.S.C. §§ 120, 121 and 365(c)

NOTE: "Except for a continued prosecution application filed under § 1.53(d), any nonprovisional application claiming the benefit of one or more prior filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. . . . Cross-references to other related applications may be made when appropriate." (See § 1.14(a)). 37 C.F.R. § 1.78(a)(2).

- ☐ "This application is a
☐ continuation
☐ continuation-in-part
☐ divisional

of copending application(s)

- ☐ application number 0 / _____ filed on _____"
☐ International Application _____ filed on _____
_____ and which designated the U.S."

NOTE: The proper reference to a prior filed PCT application that entered the U.S. national phase is the U.S. serial number and the filing date of the PCT application that designated the U.S.

NOTE: (1) Where the application being transmitted adds subject matter to the International Application, then the filing can be as a continuation-in-part or (2) if it is desired to do so for other reasons then the filing can be as a continuation.

NOTE: The deadline for entering the national phase in the U.S. for an international application was clarified in the Notice of April 28, 1987 (1079 O.G. 32 to 46) as follows:

"The Patent and Trademark Office considers the International application to be pending until the 22nd month from the priority date if the United States has been designated and no Demand for International Preliminary Examination has been filed prior to the expiration of the 19th month from the priority date and until the 32nd month from the priority date if a Demand for International Preliminary Examination which elected the United States of America has been filed prior to the expiration of the 19th month from the priority date, provided that a copy of the international application has been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively. If a copy of the international application has not been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively, the international application becomes abandoned as to the United States 20 or 30 months from the priority date respectively. These periods have been placed in the rules as paragraph (h) of § 1.494 and paragraph (i) of § 1.495. A continuing application under 35 U.S.C. 365(c) and 120 may be filed anytime during the pendency of the international application."

- ☐ "The nonprovisional application designated above, namely application _____ / _____, filed _____, claims the benefit of U.S. Provisional Application(s) No(s).:

APPLICATION NO(S).:

FILING DATE

_____/_____"
_____/_____"
_____/_____"

- ☐ Where more than one reference is made above, please combine all references into one sentence.

18. Relate Back—35 U.S.C. § 119 Priority Claim for Prior Application

The prior U.S. application(s), including any prior International Application designating the U.S., identified above in item 17B, in turn itself claim(s) foreign priority(ies) as follows:

Country	Appln. no.	Filed on
---------	------------	----------

The certified copy(ies) has (have)

- ☐ been filed on _____, in prior application 0 / _____, which was filed on _____.
- ☐ is (are) attached.

WARNING: The certified copy of the priority application that may have been communicated to the PTO by the International Bureau may not be relied on without any need to file a certified copy of the priority application in the continuing application. This is so because the certified copy of the priority application communicated by the International Bureau is placed in a folder and is not assigned a U.S. serial number unless the national stage is entered. Such folders are disposed of if the national stage is not entered. Therefore, such certified copies may not be available if needed later in the prosecution of a continuing application. An alternative would be to physically remove the priority documents from the folders and transfer them to the continuing application. The resources required to request transfer, retrieve the folders, make suitable record notations, transfer the certified copies, enter and make a record of such copies in the Continuing Application are substantial. Accordingly, the priority documents in folders of international applications that have not entered the national stage may not be relied on. Notice of April 28, 1987 (1079 O.G. 32 to 46).

19. Maintenance of Coadependency of Prior Application

NOTE: The PTO finds it useful if a copy of the petition filed in the prior application extending the term for response is filed with the papers constituting the filing of the continuation application. Notice of November 5, 1985 (1060 O.G. 27).

A. ☐ Extension of time in prior application

(This item must be completed and the papers filed in the prior application, if the period set in the prior application has run.)

- ☐ A petition, fee and response extends the term in the pending prior application until _____.
- ☐ A copy of the petition filed in prior application is attached.

B. ☐ Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

- ☐ A conditional petition for extension of time is being filed in the pending prior application.
- ☐ A copy of the conditional petition filed in the prior application is attached.

20. Further Inventorship Statement Where Benefit of Prior Application(s) Claimed

(complete applicable item (a), (b) and/or (c) below)

- (a) ☐ This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are
- ☐ the same.
 - ☐ less than those named in the prior application. It is requested that the following inventor(s) identified for the prior application be deleted:

(type name(s) of inventor(s) to be deleted)

- (b) ☐ This application discloses and claims additional disclosure by amendment and a new declaration or oath is being filed. With respect to the prior application, the inventor(s) in this application are
- ☐ the same.
 - ☐ the following additional inventor(s) have been added:

(type name(s) of inventor(s) to be added)

- (c) The inventorship for all the claims in this application are
- ☒ the same.
 - ☐ not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made
 - ☐ is submitted.
 - ☐ will be submitted.

21. Abandonment of Prior Application (if applicable)

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

NOTE: According to the Notice of May 13, 1983 (103, TMOG 6-7), the filing of a continuation or continuation-in-part application is a proper response with respect to a petition for extension of time or a petition to revive and should include the express abandonment of the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing application.

22. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

WARNING: "The claims of a new application may be finally rejected in the first Office action in those situations where (A) the new application is a continuing application of, or a substitute for, an earlier application, and (B) all the claims of the new application (1) are drawn to the same invention claimed in the earlier application, and (2) would have been properly finally rejected on the grounds of art of record in the next Office action if they had been entered in the earlier application." M.P.E.P., § 706.07(b), 7th ed.

NOTE: Where it is possible that the claims on file will give rise to a first action final for this continuation application and for some reason an amendment cannot be filed promptly (e.g., experimental data is being gathered) it may be desirable to file a petition for suspension of prosecution for the time necessary.

(check the next item, if applicable)

- ☐ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File An Amendment (New Application Filed Concurrently)

23. Small Entity (37 C.F.R. § 1.28(a))

- ☐ Applicant has established small entity status by the filing of a statement in parent application /_____ on _____.
- ☐ A copy of the statement previously filed is included.

WARNING: See 37 C.F.R. § 1.28(a).

WARNING: "Small entity status must not be established when the person or persons signing the . . . statement can *unequivocally* make the required self-certification." M.P.E.P., § 509.03, 7th ed. (emphasis added).

24. NOTIFICATION IN PARENT APPLICATION OF THIS FILING

- ☐ A notification of the filing of this
(check one of the following)
- ☐ continuation
 - ☐ continuation-in-part
 - ☐ divisional

is being filed in the parent application, from which this application claims priority under 35 U.S.C. § 120.

Practitioner's Docket No. MSU 4.1-458

PATENT

☒ Applicant Linda S. Mansfield, Mary G. Rossano, Alice J. Murphy
and Ruth A. Vrable ☐ Patentee _____

☐ Application No. _____ ☐ Patent No. _____

☐ Filed on _____ ☐ Issued on _____

Title: VACCINE TO CONTROL EQUINE PROTOZOAL MYELOENCEPHALITIS IN HORSES

STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d))—NONPROFIT ORGANIZATION

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

Board of Trustees operating
Name of Nonprofit Organization Michigan State University

Address of Nonprofit Organization 238 Administration Building
East Lansing, Michigan 48824

TYPE OF NONPROFIT ORGANIZATION

- ☒ University or Other Institution of Higher Education
- ☐ Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America
(Name of State _____)
(Citation of Statute _____)
- ☐ Would Qualify as Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)), if Located in the United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America if Located in the United States of America
(Name of State _____)
(Citation of Statute _____)

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees to the United States Patent and Trademark Office under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention described in

- ☒ the specification filed herewith, with title as listed above.
- ☐ the application identified above.
- ☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to, and remain with, the nonprofit organization, with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e)

**NOTE: Separate statements are required from each named person, concern or organization having rights to the invention as to their status as small entities. (37 CFR 1.27).*

Each such person, concern or organization having any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern or organization is listed below.

Name _____

Address _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

Name _____

Address _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

(check the following item, if desired)


NOTE: The following verification statement need not be made in accordance with the rules published on Oct. 10, 1997, 62 Fed. Reg. 52,131, effective Dec. 1, 1997.

NOTE: "The presentation to the Office (whether by signing, filing, submitting, or later advocating) of any paper by a party, whether a practitioner or non-practitioner, constitutes a certification under § 10.18(b) of this chapter. Violations of § 10.18(b)(2) of this chapter by a party, whether a practitioner or non-practitioner, may result in the imposition of sanctions under § 10.18(c) of this chapter. Any practitioner violating § 10.18(b) may also be subject to disciplinary action. See §§ 10.18(d) and 10.23(c)(15)." 37 C.F.R. § 1.4(d)(2).

☒ I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing Daniel T. Evon, Director, Contract & Grant Administration
Title in Organization Michigan State University
Address of Person Signing 301 Administration Bldg.
East Lansing, MI 48824-1046

SIGNATURE



Date

2/11/00

VACCINE TO CONTROL EQUINE PROTOZOAL MYELOENCEPHALITIS
IN HORSES

CROSS-REFERENCE TO RELATED APPLICATION

The application claims the benefit of U.S. Provisional Patent Application Serial No. 60/152,193, filed on September 2, 1999.

5

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

None.

10 BACKGROUND OF THE INVENTION

(1) Field of the Invention

The present invention relates to vaccines and methods for making the vaccines that actively or passively protect an equid or other animal against *Sarcocystis neurona*. In particular, the present invention relates to vaccines that provide active immunity which comprise a polypeptide or DNA vaccine that contains or expresses at least one epitope of an antigen that has an amino acid sequence substantially similar to a unique 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*. The present invention further relates to a vaccine that provides passive immunity to *Sarcocystis neurona* comprising polyclonal or monoclonal antibodies against at least one epitope of an antigen substantially similar to a unique 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

30 (2) Description of Related Art

Equine protozoal myeloencephalitis (EPM) is an emerging neurological disease caused by the protozoan

parasite *Sarcocystis neurona*. In recent years, EPM has caused significant health, economic, and emotional costs to horses and their owners (reviewed by McKay et al., Veterinary Clinics of North America 13: 79-96 (1997)).

5 Opossums have been implicated as the natural reservoir of *Sarcocystis neurona* because the sexual stages of the parasite occur in the intestines of the opossum and the sporocysts are passed in the feces of the opossum. Horses accidentally eat the opossum feces containing the

10 sporocysts when they are grazing; however, because *Sarcocystis neurona* does not appear to form mature tissue cysts in equids, equids are considered to be dead end hosts. Because opossums are ubiquitous in the United States, large numbers of equids are exposed to

15 this parasite: approximately 50 to 60% of the horses nationwide (Blythe et al., J. Am. Vet. Med. Assoc. 210: 525-527 (1997), Saville et al., J. Am. Vet. Assoc. 210: 519-524 (1997), Bentz et al., J. Am. Vet. Med. Assoc. 210: 517-518 (1997)).

20 Currently, there are no adequate diagnostic tests for determining whether an equid is currently infected with *Sarcocystis neurona*. A Western blot test was developed to detect antibodies to *Sarcocystis neurona* in cerebrospinal fluid of equids suspected of

25 having EPM; however, these Western blot assays have not been reliable in predicting the presence of *Sarcocystis neurona* due to the prevalence in equids of cross-reacting antibodies to other *Sarcocystis* species (Granstom et al. J. Vet. Diag. Invest. 5: 88-90 (1993),

30 Fenger et al., Vet. Parasitol. 68: 199-213 (1997), Bentz et al., *ibid.*, Saville et al., *ibid.*, Blythe et al., *ibid.*).

Currently, there are no vaccines to protect equids from the parasite, and current treatment regimens

are effective in only about 50% of the equids (Martenuik
et al., Proceedings, Conference of Research Workers on
Animal Disease, Chicago, Illinois, 1997). However,
these studies on treatment efficacy were based on a low
5 number of horses. The U.S. Department of Agriculture
(USDA), Animal and Plant Health Inspection Service
(APHIS), National Animal Health Monitoring System
(NAHMS) of the Needs Assessment Survey (NAS) has
designated EPM as one of the top two infectious diseases
10 of national importance to the horse industry. Among
veterinarians and race horse owners, EPM has been ranked
as the leading health care concern. In particular, 58%
of the race horse owners ranked EPM as the top health
care concern.

15 Since there are no vaccines for EPM and EPM is
a significant health concern of the equine industry,
considerable effort has been directed towards developing
therapeutic methods for treating EPM. For example, U.S.
Patent No. 5,935,591 to Rossignol *et al.* describes using
20 thiazolides as a treatment for EPM; U.S. Patent No.
5,883,095 to Granstrom *et al.* describes using triazine-
based anti-coccidials as a treatment for EPM; U.S.
patent No. 5,830,893 to Russel describes using
triazinediones as a treatment for EPM; U.S. Patent No.
25 5,747,476 to Russel describes using a combination of
pyrimethamine and a sulfonamide, preferably sulfadiazine
in the absence of known therapeutic amounts of
trimethoprim as a treatment for EPM; and U.S. Patent No.
30 5,925,622 to Rossignol *et al.* describes using aryl
glucuronide of 2-hydroxy-N-(5-nitro-2-thiazolyl)
benzamide as a treatment for EPM.

Treatment for EPM is expensive and cumbersome
because of the long duration required to achieve
positive results. Because many horses cannot be
35 successfully treated, economically and emotionally

valuable animals have been lost to EPM. However, the extent of EPM's economic impact is even greater because of the large sums of money spent by horse owners for treating lame horses which have been incorrectly diagnosed with EPM, for giving prophylactic treatments that have no scientific basis, and for finding positive post-race drug test results.

EPM has been the cause of hysteria in the equid industry. The small amount of scientific data available on EPM supports a high exposure rate of equids, but there are no data available that document the rate of clinical disease resulting from exposure to the parasite. Because of this, horse owners and veterinarians assume that the rate of clinical disease is high. As a result, several alarming consequences have arisen. Equids with lameness or other neurological diseases are being misdiagnosed as having EPM. People whose livelihoods depend on horses are resorting to medicating all their horses all of the time with antimicrobials. This approach to treating EPM is very widespread in the racing industry. However, this indiscriminate use of antimicrobials has the potential of leading to resistant bacteria such as *Salmonella*, *E. coli*, etc. which will then enter the environment and pose a risk for humans and animals. Thus, the repercussions of EPM may extend beyond a disease that merely affects the horse industry. All of the repercussions of EPM are expensive, decrease the value realized to the U.S. equid industry, and raise the specter of a public health problem of immense proportions.

Therefore, there is a need for a treatment of EPM that is effective and has little or no side-effects.

SUMMARY OF THE INVENTION

The present invention provides vaccines and methods for making the vaccines that protect an equid or other animal host against *Sarcocystis neurona*. In particular, the present invention provides a vaccine that elicits active immunity against *Sarcocystis neurona* which contains at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. The present invention further provides a DNA vaccine that elicits active immunity against *Sarcocystis neurona* comprising a DNA encoding at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*.

The present invention further provides a vaccine for providing passive immunity to a *Sarcocystis neurona* infection comprising antibodies which are against at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. In particular, a vaccine wherein the antibodies are selected from the group consisting of polyclonal antibodies and monoclonal antibodies against a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. In a preferred embodiment of the vaccine, the vaccine is provided in a pharmaceutically accepted carrier.

Further, the present invention further provides a vaccine for active immunization of an equid against a *Sarcocystis neurona* infection comprising an antigen containing at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. In one embodiment of the present invention, the antigen is a recombinant polypeptide produced in a plasmid in a microorganism other than *Sarcocystis neurona*, preferably, in an *E. coli*. In a preferred embodiment, the vaccine is provided in a

pharmaceutically accepted carrier.

Further, the present invention provides for a vaccine wherein the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona* antigen is provided as a fusion polypeptide wherein an amino end and/or a carboxyl end of the antigen is fused to all or a portion of a polypeptide that facilitates the isolation of the antigen from the microorganism in which the antigen is produced. In a preferred embodiment, the polypeptide is selected from the group consisting of glutathione S-transferase, protein A, maltose binding protein, and polyhistidine.

The present invention also provides a vaccine for protecting an equid from a *Sarcocystis neurona* infection comprising a DNA that encodes at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*. In a preferred embodiment, the DNA is operably linked to a promoter to enable transcription of the DNA in the cell of an equid. Preferably, the vaccine is provided in a pharmaceutically accepted carrier.

The present invention further provides a method for vaccinating an equid against a *Sarcocystis neurona* infection comprising: (a) providing a recombinant antigen of the *Sarcocystis neurona* produced from a microorganism culture wherein the microorganism contains a DNA that encodes a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*; and (b) vaccinating the equid. Preferably, the vaccine is in a pharmaceutically accepted carrier.

In a preferred embodiment of the method, the recombinant antigen is a fusion polypeptide which is fused at the amino terminus and/or carboxyl terminus to a polypeptide that facilitates the isolation of the recombinant antigen. In particular, the polypeptide is

all or a portion of the polypeptide selected from the group consisting of glutathione S-transferase, protein A, maltose binding protein, and polyhistidine. Further, the method includes producing the antigen from a DNA which is in a plasmid in a microorganism wherein the DNA is operably linked to a promoter which enables transcription of the DNA to produce the recombinant antigen for the vaccine.

The present invention further provides a method for vaccinating an equid against a *Sarcocystis neurona* infection comprising: (a) providing in a carrier solution a DNA in a plasmid which encodes at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*; and (b) vaccinating the equid with the DNA in the carrier solution. Preferably, the DNA is in a carrier solution that is pharmaceutically accepted for DNA vaccines. In a preferred embodiment, the DNA is operably linked to a promoter to enable transcription of the DNA in a cell of the equid.

The present invention further provides a method for providing passive immunity to a *Sarcocystis neurona* infection in an equid comprising: (a) providing antibodies selected from the group consisting of polyclonal antibodies and monoclonal antibodies which are against at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*; and (b) inoculating the equid. Preferably, the antibodies are provided in a pharmaceutically accepted carrier.

Further still, the present invention provides a method for producing an antigen comprising: (a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa

antigen of *Sarcocystis neurona* and a polypeptide that facilitates isolation of the fusion polypeptide; (b) culturing the microorganism in a culture to produce the fusion polypeptide; and (c) isolating the fusion polypeptide. In one embodiment, the fusion polypeptide is isolated by affinity chromatography which can be affinity chromatography that comprises an IgG-linked resin when the polypeptide consists of all or a portion of protein A, an Ni^{2+} resin when the polypeptide is polyhistidine, amylose resin when the polypeptide is all or part of the maltose binding protein, or glutathione Sepharose 4B resin when the polypeptide is all or part of glutathione S-transferase.

Further still, the present invention provides a method for producing an antibody comprising: (a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona* linked to a polypeptide that facilitates isolation of the fusion polypeptide; (b) culturing the microorganism in a culture to produce the fusion polypeptide; (c) isolating the fusion polypeptide; (d) producing the antibody from the polypeptide. In a preferred embodiment, the polypeptide is removed from the antigen portion of the fusion polypeptide.

And further still, the present invention provides a method for producing a monoclonal antibody comprising: (a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona* linked to a polypeptide that facilitates isolation of the fusion polypeptide; (b) culturing the microorganism in a culture to produce the fusion polypeptide; (c)

isolating the fusion polypeptide; and (d) producing the monoclonal antibody from the polypeptide. Preferably, the polypeptide is removed from the antigen portion of the fusion polypeptide.

5 The present invention comprises a vaccine for an equid comprising an isolated recombinant protein encoded by a cDNA produced from RNA of *Sarcocystis neurona* encoding a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen, and a vaccine carrier. In another
10 embodiment of the present invention, the vaccine for an equid comprises a recombinant virus vector containing DNA encoding a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*, and a vaccine carrier. In particular, the recombinant virus is selected from
15 the group consisting of equine herpesvirus, vaccinia virus, canary pox virus, raccoon poxvirus, adenovirus, and baculovirus. In an embodiment further still, the present invention comprises a DNA vaccine for an equid comprising a plasmid containing DNA encoding a 16 (± 4)
20 kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

 The present invention provides a method for protecting an equid against *Sarcocystis neurona* which comprises providing a vaccine that when injected into
25 the equid causes the equid to produce antibodies and cell mediated immunity against a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of the *Sarcocystis neurona* wherein the antibodies prevent infection by the *Sarcocystis neurona*. In particular, the vaccine
30 comprises the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen in a vaccine carrier. The present invention further provides a vaccine comprising a recombinant virus vector that expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen. In particular, the
35 recombinant virus vector is selected from the group

consisting of equine herpesvirus, vaccinia virus, canary pox virus, raccoon poxvirus, and adenovirus. The present invention further still provides a vaccine which comprises a DNA plasmid encoding the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen.

The present invention further comprises a monoclonal antibody that selectively binds to a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. The present invention also comprises an isolated recombinant protein encoded by a cDNA produced from RNA of *Sarcocystis neurona* encoding a protein which is a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen. Thus, the present invention further comprises an isolated DNA that encodes a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. Finally, the present invention comprises a bacterial clone containing a plasmid comprising a DNA encoding a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*. In particular, the bacterial clone expresses the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*.

It is therefore an object of the present invention to provide a vaccine for the prophylactic or therapeutic treatment of protozoal myeloencephalitis in equids. In particular, it is an object of the present invention to provide a vaccine for providing active immunity against *Sarcocystis neurona* which comprises a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*.

It is also an object of the present invention to provide a vaccine that provides passive immunity in an equid against *Sarcocystis neurona* which comprises antibodies against a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona*.

These and other objects of the present invention will become increasingly apparent by reference to the following embodiments and drawings.

5 DESCRIPTION OF PREFERRED EMBODIMENTS

The following definitions are provided herein to promote a better understanding of the present invention.

10 The term "antibody" as used herein refers to an immunoglobulin molecule with the capacity to bind with a specific antigen as the result of a specific immune response. Immunoglobulins are serum proteins made up of light and heavy polypeptide chains and divisible into classes, which contain within them
15 antibody activities toward a wide range of antigens.

20 The term "polyclonal antibody" as used herein refers to a mixed population of antibodies made against a particular pathogen or antigen. In general, the population contains a variety of antibody groups, each group directed towards a particular epitope of the pathogen or antigen. To make polyclonal antibodies, the whole pathogen or an isolated antigen is introduced by inoculation or infection into a host which induced the host to make antibodies against the pathogen or antigen.

25 The term "monoclonal antibody" as used herein refers to antibodies produced by a single line of hybridoma cells all directed towards one epitope on a particular antigen. The antigen used to make the monoclonal antibody can be provided as an isolated protein of the pathogen or the whole pathogen. A
30 hybridoma is a clonal cell line that consists of hybrid cells formed by the fusion of a myeloma cell and a specific antibody-forming cell. In general, monoclonal antibodies are of mouse origin; however, monoclonal
35 antibody also refers to a clonal population of an

antibody made against a particular epitope of an antigen produced by phage display technology or method that is equivalent to phage display or hybrid cells of non-mouse origin.

5 The term "antigen" as used herein refers to a substance which stimulates production of antibody or sensitized cells during an immune response. An antigen includes the whole pathogen or a particular protein of the pathogen. An antigen consists of multiple epitopes,
10 each epitope of which is capable of causing the production of an antibody against the particular epitope.

 The term "epitope" as used herein refers to an immunogenic region of an antigen which is recognized by
15 a particular antibody molecule. In general, an antigen will possess one or more epitopes, each capable of binding an antibody that recognizes the particular epitope. An antibody can recognize a contiguous epitope which is an epitope that is a linear sequence of amino
20 acids in the antigen molecule, or a non-contiguous epitope which is an epitope that spans non-contiguous amino acids in the antigen which have been brought together because of the three-dimensional structure of the antigen.

25 The term "active immunity" as used herein includes both antibody immunity and/or cell mediated immunity against *Sarcocystis neurona* induced by vaccinating an equid with the vaccine of the present invention comprising the 16 (\pm 4) kDa antigen and/or 30
30 (\pm 4) kDa antigen.

 The term "passive immunity" as used herein refers to the protection against *Sarcocystis neurona* provided to an equid as a result of vaccinating the equid with a vaccine comprising antibodies against the
35 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen.

The present invention provides a vaccine that protects equids against *Sarcocystis neurona*. In a preferred embodiment, the vaccine consists of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen in a subunit vaccine. Preferably, the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen are produced in a recombinant bacterium or eukaryote expression vector which produces the proteins which are then isolated to make the vaccine. In another embodiment of the vaccine, the vaccine is a DNA vaccine that comprises a recombinant DNA molecule, preferably in a plasmid, that comprises DNA encoding all or part of the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen. In another embodiment of the vaccine, the recombinant DNA is inserted into a virus vector to provide a live vaccine which is a recombinant DNA virus. In U.S. Serial No. 09/156,954, filed on September 18, 1998, which is hereby incorporated herein by reference, it was disclosed that *Sarcocystis neurona* possesses two unique antigens, a 16 (± 4) antigen and a 30 (± 4) kDa antigen. These antigens do not react with antibodies from other *Sarcocystis* spp. Thus, these antigens are useful for producing vaccines that protect equids against *Sarcocystis neurona*.

The route of administration for the vaccines of the present invention can include, but is not limited to, intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, intraocular, and oral as well as transdermal or by inhalation or suppository. The preferred routes of administration include intranasal, intramuscular, intraperitoneal, intradermal, and subcutaneous injection. The vaccine can be administered by means including, but not limited to, syringes, needle-less injection devices, or microprojectile bombardment gene guns (biolistic bombardment).

The vaccines of the present invention are formulated in pharmaceutically accepted carriers according to the mode of administration to be used. One skilled in the art can readily formulate a vaccine that comprises the polypeptide or DNA of the present invention. In cases where intramuscular injection is preferred, an isotonic formulation is preferred. Generally, additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol, and lactose. In particular cases, isotonic solutions such as phosphate buffered saline are preferred. The formulations can further provide stabilizers such as gelatin and albumin. In some embodiments, a vaso-constriction agent is added to the formulation. The pharmaceutical preparations according to the present invention are provided sterile and pyrogen free. However, it is well known by those skilled in the art that the preferred formulations for the pharmaceutically accepted carrier which comprise the vaccines of the present invention are those pharmaceutical carriers approved in the regulations promulgated by the the United States Department of Agriculture, or equivalent government agency in a foreign country such as Canada or Mexico, for polypeptide, recombinant vector, antibody, and DNA vaccines intended for veterinary applications. Therefore, the pharmaceutically accepted carriers for commercial production of the vaccines of the present invention are those carriers that are already approved or will at some future date be approved by the appropriate government agency in the United States of America or foreign country.

Inoculation of an equid is preferably by a single vaccination which in the case of polypeptide, recombinant vector, and DNA vaccines produces a full, broad immunogenic response. In another embodiment of

the present invention, the equid is subjected to a series of vaccinations to produce a full, broad immune response. When the vaccinations are provided in a series, the vaccinations can be provided between about
5 24 hours apart to two weeks or longer between vaccinations. In certain embodiments, the equid is vaccinated at different sites simultaneously.

The vaccines of the present invention are generally intended to be a prophylactic treatment which
10 prevents *Sarcocystis neurona* from establishing an infection in an equid. However, the vaccines are also intended for the therapeutic treatment of equids already infected with *Sarcocystis neurona*. For example, antibody vaccines of the present invention are suitable
15 for therapeutic purposes. However, vaccines that provide active immunity have also been shown to be effective when given as a therapeutic treatment against various diseases. Thus, the immunity that is provided by the present invention can be either active immunity
20 or passive immunity and the intended use of the vaccine can be either prophylactic or therapeutic.

With respect to the above, the vaccine that elicits active immunity in a host can be a polypeptide vaccine or a DNA vaccine which produces the polypeptide
25 in a vaccinated host. Alternatively, the vaccine can be a recombinant microorganism vaccine that expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen or a recombinant virus vector that expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen.

Thus, in one embodiment of the present invention, the active immunity is provided by a vaccine that consists of the isolated 16 (± 4) kDa antigen and/or
30 30 (± 4) kDa antigen or the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen as a fusion polypeptide wherein the
35 amino and/or carboxyl terminus is fused to another

polypeptide, preferably a polypeptide that facilitates isolation of the fusion polypeptide. The fusion polypeptide comprising the vaccine is preferably produced *in vitro* in an expression system from a DNA that encodes the antigens which is in a microorganism such as bacteria, yeast, or fungi; in eukaryote cells such as a mammalian or an insect cell; or, in a virus expression vector such as adenovirus, poxvirus, herpesvirus, Simliki forest virus, baculovirus, bacteriophage, or sendai virus. In particular, suitable bacterial strains for producing the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen or the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen as fusion polypeptides include *Escherichia coli*, *Bacillus subtilis*, or any other bacterium that is capable of expressing heterologous polypeptides. Suitable yeast for expressing the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen or 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen as fusion polypeptides include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Candida*, or any other yeast capable of expressing heterologous polypeptides. Methods for using the aforementioned and the like to produce recombinant polypeptides for vaccines are well known in the art.

For any of the above, transformed host cells are cultured under conditions which produce the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen or the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen as fusion polypeptides. The resulting expressed polypeptides can be isolated from the culture, medium or cell extracts, using purification methods such as gel filtration, affinity chromatography, ion exchange chromatography, or centrifugation. Furthermore, the present invention further includes polypeptides that comprise only those epitopes of the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa

antigen which are responsible for conferring protective immunity against *Sarcocystis neurona*. It is also understood that antigens of other *Sarcocystis* spp. that correspond to the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona* are within the scope of the present invention.

DNA encoding the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen can be obtained from a genome preparation of *Sarcocystis neurona* using a polymerase chain reaction (PCR) method that uses DNA primers which correspond to the nucleotide sequences encoding the amino and carboxyl ends of the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen. Preferably the 5' ends of the primers contain a restriction enzyme site that facilitates the subsequent steps of constructing 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen expression systems. Alternatively, the DNA primers can correspond to an internal region of the nucleotide sequence encoding the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen for producing a DNA encoding a particular epitope of the antigen. Primer design and PCR methods are well known in the art.

In a preferred embodiment, the DNA is in a plasmid and the DNA is operably linked to a promoter which effects the expression of the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen in a microorganism, preferably *E. coli*. As used herein, the term "operably linked" means that the polynucleotide of the present invention and a DNA containing an expression control sequence, e.g., transcription promoter and termination sequences, are situated in a vector or cell such that expression of the antigen encoded by the polynucleotide is regulated by the expression control sequence. Methods for cloning DNA such as the DNA encoding the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen and operably

linking DNA containing expression control sequences thereto are well known in the art. Expression of the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen in a microorganism enables the antigen to be produced using fermentation technologies which are used commercially for producing large quantities of recombinant polypeptides.

To facilitate isolation of the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen produced as above, a fusion polypeptide is made wherein the antigen is linked to another polypeptide which enables isolation by affinity chromatography. Preferably, a fusion polypeptide is made using one of the aforementioned expression systems. Therefore, the DNA encoding the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen is linked to a DNA encoding a second polypeptide to produce a fusion polypeptide wherein the amino and/or carboxyl terminus of the antigen is fused to a polypeptide which allows for the simplified recovery of the antigen as a fusion polypeptide. The fusion polypeptide can also prevent the antigen from being degraded during purification. While a vaccine comprising the fusion polypeptide is efficacious, in some instances it can be desirable to remove the second polypeptide after the purification. Therefore, it is also contemplated that the fusion polypeptide comprise a cleavage site at the junction between the antigen and the polypeptide. The cleavage site consists of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence of that site. Examples of such cleavage sites that are contemplated include the enterokinase cleavage site which is cleaved by enterokinase, the factor Xa cleavage site which is cleaved by factor Xa, and the GENENASE cleavage site which is cleaved by GENENASE (GENENASE is a trademark of New England Biolabs, Beverly,

Massachusetts).

5 An example of a procaryote expression system
for producing the 16 (± 4) kDa antigen and/or 30 (± 4) kDa
antigen is the Glutathione S-transferase (GST) Gene
Fusion System available from Amersham Pharmacia Biotech,
Piscataway, New Jersey, which uses the pGEX-4T-1
expression vector plasmid. The DNA encoding the antigen
is fused in frame with the GST gene. The GST part of
the fusion polypeptide allows the rapid purification of
10 the fusion polypeptide using glutathione Sepharose 4B
affinity chromatography. After purification, the GST
portion of the fusion polypeptide can be removed by
cleavage with a site-specific protease such as thrombin
or factor Xa to produce a polypeptide free of the GST
15 gene. The antigen free of GST is produced by a second
round of glutathione Sepharose 4B affinity
chromatography.

20 Another example for producing the 16 (± 4) kDa
antigen and/or 30 (± 4) kDa antigen is a method which
links in-frame with the gene encoding the antigen,
codons that encode polyhistidine. The polyhistidine
preferably comprises six histidine residues which allows
purification of the fusion polypeptide by metal affinity
chromatography, preferably nickel affinity
25 chromatography. To produce the native antigen free of
the polyhistidine, a cleavage site such as an
enterokinase cleavage site is fused in frame between the
codons encoding the polyhistidine and the codons
encoding the antigen. The native polypeptide free of
30 the polyhistidine is made by removing the polyhistidine
by cleavage with enterokinase. The antigen free of the
polyhistidine is produced by a second round of metal
affinity chromatography. This method was shown to be
useful for preparing the LcrV antigen of *Y. pestis* which
35 was disclosed in Motin et al. *Infect. Immun.* 64: 4313-

4318 (1996), which is hereby incorporated herein by reference. The Xpress System available from Invitrogen, Carlsbad, California is an example of a commercial kit which is available for making and then isolating polyhistidine-polypeptide fusion proteins.

A method further still for producing the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen is disclosed by Motin *et al.*, *Infect. Immun.* 64: 3021-3029 (1995), which is hereby incorporated herein by reference. Motin *et al.* disclosed a DNA encoding a fusion polypeptide consisting of the DNA encoding an antigen linked to DNA encoding a portion of protein A wherein DNA encoding an enterokinase cleavage site is interposed between the DNA encoding protein A and the antigen. The protein A enables the fusion polypeptide to be isolated by IgG affinity chromatography, and the antigen free of the protein A is produced by cleavage with an enterokinase. The protein A is then removed by a second round of IgG affinity chromatography.

Another method for producing polypeptide vaccines against *Sarcocystis neurona* is based on methods disclosed in U. S. Patent No. 5,725,863 to Daniels *et al.*, which is hereby incorporated herein by reference. The Daniels method can be used to make the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen vaccine of the present invention which consists of an enterotoxin which has inserted therein upwards of 100 amino acid residues of the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen. Another method that can be used to make the polypeptide vaccines of the present invention is disclosed in U.S. Patent No. 5,585,100 to Mond *et al.*, which is hereby incorporated herein by reference, which provides methods for making various fusion polypeptide vaccines. Further methods are disclosed in U.S. Patent No. 5,589,384 to Liscombe, which is hereby incorporated herein by

reference. Finally, the pMAL Fusion and Purification System available from New England Biolabs is another example of a method for making a fusion polypeptide wherein a maltose binding protein is fused to the antigen. The maltose binding protein facilitates isolation of the fusion polypeptide by amylose affinity chromatography. The maltose binding protein can subsequently be released by cleavage with any of the aforementioned cleavage enzymes.

While bacterial methods are used to produce the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen, it can be desirable to produce the antigen in a eukaryote expression system. A particularly useful system is the baculovirus expression system which is disclosed in U.S. Patent No. 5,229,293 to Matsuura et al., which is hereby incorporated herein by reference. Baculovirus expression vectors suitable to produce the antigen are the pPbac and pMbac vectors from Stratagene; and the Bac-N-Blue vector, the pBlueBac4.5 vector, pBlueBacHis2-A,B,C, and the pMelBac available from Invitrogen, Carlsbad, California.

Another eukaryote system useful for expressing the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen is a yeast expression system such as the ESP Yeast Protein Expression and Purification System available from Stratagene. Another yeast expression system is any one of the *Pichia*-based Expression systems from Invitrogen. Mammalian expression systems are also embraced by the present invention. Examples of mammalian expression systems are the LacSwitch II system, the pBK Phagemid, pXT1 vector system, and the pSG5 vector system from Stratagene; the pTargetT mammalian expression vector system, the pSI mammalian expression vector, pCI mammalian expression vector, and pAdVantage vectors available from Promega Corporation, Madison, Wisconsin;

and the Ecdysone-Inducible Mammalian Expression System, pCDM8, pcDNA1.1, and pcDNA1.1/Amp available from Invitrogen.

Another method for producing the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen in a eukaryote expression system is to insert DNA encoding the antigen into the genome of a eukaryote cell or in a eukaryote virus expression vector such as herpesvirus, poxvirus, or adenovirus to make a recombinant virus that expresses the antigen. The recombinant virus vectors are used to infect mammalian cells wherein the antigens are produced in the cell. U.S. Patent No. 5,223,424 to Cochran et al., which is hereby incorporated herein by reference, provides methods for inserting genes into herpesvirus expression vectors. U.S. Patent Nos. 5,338,683 and 5,494,807 to Paoletti et al. and U.S. Patent No. 5,935,777 to Moyer et al., which are hereby incorporated herein by reference, provide methods for inserting genes into poxvirus expression vectors such as vaccinia virus, entomopoxvirus, and canary poxvirus. In another embodiment, the genes encoding the antigen can be inserted into a defective virus such as the herpesvirus amplicon vector which is disclosed in U.S. Patent No. 5,928,913 to Efsthathiou et al., which is hereby incorporated herein by reference. In any of the aforementioned virus vectors, the gene encoding the antigen are operably linked to a eukaryote promoter at the 5' end of the DNA encoding the protein and a eukaryote termination signal and poly(A) signal at the 3' end of the gene. Examples of such promoters are the cytomegalovirus immediate-early (CMV) promoter, the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter, the simian virus 40 (SV40) immediate-early promoter, and inducible promoters such as the metallothionein promoter. An example of a DNA having a termination and

poly(A) signal is the SV40 late poly(A) region. Another example of a viral expression system suitable for producing the antigen is the Sindbis Expression system available from Invitrogen. The use of these commercially available expression vectors and systems are well known in the art.

While subunit vaccines comprising the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen generally provide good humoral protection, it can be desirable to provide the antigen as a component of a live recombinant vector vaccine. Therefore, the present invention further embraces recombinant virus vector vaccines wherein DNA encoding the antigen is inserted into a recombinant virus vector. In one embodiment of the recombinant virus vector vaccine, the DNA encoding the antigen is inserted into a herpesvirus vector according to the method taught by Cochran et al. in U.S. Patent No. 5,233,424, which is hereby incorporated herein by reference. It is particularly desirable to have a recombinant virus vector vaccine against *Sarcocystis neurona* that is fetal safe, which allows the vaccine to be given to pregnant mares without affecting the fetus. U.S. Patent Nos. 5,741,696 and 5,731,188 to Cochran et al., which are hereby incorporated herein by reference, teach methods for making and using live recombinant herpesvirus vaccine vectors which are fetal safe.

Other recombinant virus vector vaccines embraced by the present invention, include but are not limited to, adenovirus, adeno-associated virus, parvovirus, and various poxvirus vectors to express the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen. For example, U.S. Patent Nos. 5,338,683 and 5,494,807 to Paoletti et al. teach recombinant virus vaccines consisting of either vaccinia virus or canary poxvirus expressing foreign antigens; and U.S. Patent No.

5,266,313 to Esposito et al. teaches recombinant raccoon poxvirus vectors expressing foreign antigens. Therefore, the present invention embraces recombinant poxvirus vaccines that express the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen made according to the methods taught in any one of U.S. Patent Nos. 5,338,683; 5,494,807; and 5,935,777, which are hereby incorporated herein by reference.

While the above refer to DNA sequences encoding the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen, the present invention also includes RNA sequences for encoding the antigen.

The present invention further includes vaccines that comprise the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen or particular epitopes of the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen as components of a heat-stable spore delivery system made according to the method taught in U.S. Patent No. 5,800,821 to Acheson et al., which is hereby incorporated herein by reference. Therefore, the present invention provides a genetically engineered bacterial cell containing DNA encoding the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen. When the recombinant bacterial spore vaccine is orally administered to the equid, the spores germinate in the gastrointestinal tract of the animal and the bacteria expresses the antigen which comes into contact with the animal's immune system and elicits an immune response. The vaccine has the advantage of being heat stable; therefore, it can be stored at room temperature for an indefinite period of time.

Another embodiment of the *Sarcocystis neurona* vaccine is a DNA vaccine that elicits an active immune response in an equid. The DNA vaccine consists of DNA having a DNA sequence substantially similar to the DNA sequence that encodes the 16 (± 4) kDa antigen and/or 30

(±4) kDa antigen. The DNA encoding the antigen is operably linked at or near its start codon to a promoter that enables transcription of the antigen from the DNA when the DNA is the cells of the equid. Preferably, the DNA is in a plasmid. Promoters for expression of DNAs in DNA vaccines are well known in the art and include among others such promoters as the RSV LTR promoter, the CMV immediate early promoter, and the SV40 T antigen promoter. It is further preferred that the DNA is operably linked at the or near the termination codon of the sequence encoding antigen to a DNA fragment comprising a transcription termination signal and poly(A) recognition signal. Preferably, the vaccine is in an accepted pharmaceutical carrier or in a lipid or liposome carrier similar to those disclosed in U.S. Patent No. 5,703,055 to Felgner, which is hereby incorporated herein by reference. The DNA can be provided to the equid by a variety of methods such as intramuscular injection, intrajet injection, or biolistic bombardment. Making DNA vaccines and methods for their use are provided in U.S. Patent Nos. 5,589,466 and 5,580,859, both to Felgner, which are hereby incorporated herein by reference. Finally, a method for producing pharmaceutical grade plasmid DNA is taught in U.S. Patent No. 5,561,064 to Marquet *et al.*, which is hereby incorporated herein by reference.

Therefore, using the abovementioned methods, DNA vaccines that express the 16 (±4) kDa antigen and/or 30 (±4) kDa antigen are made and used to vaccinate equids against *Sarcocystis neurona*. The advantage of the DNA vaccine is that the DNA is conveniently propagated as a plasmid which is a simple and inexpensive means for producing a vaccine, and since the vaccine is not live, the regulatory difficulties associated with getting recombinant virus vaccines

approved are not present. One skilled in the art would appreciate that while the polypeptide produced for the polypeptide vaccine or by the DNA vaccine can be the entire 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen, the present invention also includes polypeptide and DNA vaccines wherein the vaccine consists of a subfragment of the antigen which comprises one or more epitopes of the antigen or a DNA encoding one or more epitopes of the antigen. Furthermore, the polypeptide and DNA vaccines of the present invention can comprise synthetically produced polypeptides or DNA which are made by chemical synthesis methods well known in the art.

While the DNA and polypeptide provided herein is from *Sarcocystis neurona*, the present invention further encompasses similar antigens from other *Sarcocystis* spp. Thus, it is anticipated that the vaccines and methods disclosed herein are useful for producing vaccines against other *Sarcocystis* spp.

In another embodiment of the present invention, the vaccine provides passive immunity to *Sarcocystis neurona*. A vaccine that elicits passive immunity against *Sarcocystis neurona* consists of polyclonal antibodies or monoclonal antibodies that are against the unique 16 (± 4) and/or 30 (± 4) antigen of *Sarcocystis neurona*.

To make a passive immunity vaccine comprising polyclonal antibodies, the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen or one or more epitopes therefrom are injected into a suitable host for preparing the antibodies, preferably the host is a horse, swine, rabbit, sheep, or goat. Methods for producing polyclonal antibody vaccines from these hosts are well known in the art. By way of brief example, the antigen is admixed with an adjuvant such as Freund's complete or

the less toxic TiterMax available from CytRx Corp., Norcross, Georgia, which then administered to the host by methods well known in the art.

5 The passive immunity vaccine can comprise one or more monoclonal antibodies against one or more epitopes of the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen. Methods and hybridomas for producing monoclonal antibodies are well known in the art. While monoclonal antibodies can be made using hybridoma
10 technologies well known in the art, the monoclonal antibodies against the antigen can also be made according to phage display methods such as that disclosed in U.S. Patent No. 5,977,322 to Marks *et al.*, which is hereby incorporated herein by reference.
15 Equinized antibodies against the antigen can be made according to methods which have been used for humanizing antibodies such as those disclosed in U.S. Patent Nos. 5,693,762 and 5,693,761 both to Queen *et al.*, which are hereby incorporated herein by reference. A phage
20 display kit that is useful for making monoclonal antibodies is the Recombinant Phage Antibody System available from Amersham Pharmacia Biotech.

To make the vaccines of the present invention, the genes encoding the 16 (\pm 4) kDa antigen and/or 30
25 (\pm 4) kDa antigen are identified using monoclonal antibodies against the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen to screen a cDNA expression library made from mRNA isolated from *Sarcocystis neurona*. Since expression of certain *Sarcocystis neurona* proteins is
30 stage specific, not only are cDNA expression libraries made from mRNA isolated from *Sarcocystis neurona* grown in culture but cDNA libraries are also made from mRNA isolated from *Sarcocystis neurona* at various stages of development, i.e., the merozoite, sporocyst, and
35 sarcocyst stages. Methods for screening cDNA expression

libraries with monoclonal antibodies are described in *Molecular Cloning: A Laboratory Manual, Second Edition*, edited by Sambrook et al. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). The expression library can be a plasmid-based expression library that uses a pUC, pUR, pEX or a lambda-based expression library. Preferably, the library is a ZAP EXPRESS vector (available from Stratagene, La Jolla, California) which is a hybrid lambda-plasmid vector used to construct cDNA libraries. RNA is isolated using a Stratagene RNA isolation kit and cDNA is made using the ZAP EXPRESS cDNA Synthesis kit (available from Stratagene). The library is screened using monoclonal antibodies against the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen and the picoBLUE Immunoscreening kit (available from Stratagene).

An important aspect of any vaccination program is to be able to distinguish animals vaccinated against a disease from animals infected with the disease. Therefore, the present invention further includes methods that distinguish equids vaccinated with the vaccine of the present invention from equids infected with *Sarcocystis neurona*, or equids vaccinated with whole-organism *Sarcocystis neurona* vaccine preparations, or equids never exposed to *sarcocystis neurona*. In one embodiment, to distinguish vaccinated equids from infected equids, a biological sample from an equid is tested for the presence of antibodies against *Sarcocystis neurona* specific antigens that are in addition to the 16 (± 4) antigen and 30 (± 4) kDa antigen which are induced by the vaccine. For example, Granstrom et al. in J. Vet. Diagn. Invest. 5: 88-90 (1993) identified by gel electrophoresis followed by Western blot eight *Sarcocystis neurona* antigens; 70 kDa, 24 kDa, 23.5 kDa, 22.5 kDa, 13 kDa, 11 kDa, 10.5 kDa,

and 10 kDa, of which at least three (22.5 kDa, 13 kDa, and 10.5 kDa) were common to all seven equids infected with *Sarcocystis neurona*. Therefore, an equid that had antibodies against any of the above *Sarcocystis neurona* antigens in addition to the 16 (\pm 4) and 30 (\pm 4) kDa antigens would be infected with, or exposed to, *Sarcocystis neurona* whereas an equid that had antibodies against the 16 (\pm 4) antigen and 30 (\pm 4) kDa antigen but not against any one of the other *Sarcocystis neurona* antigens would be an equid that had been vaccinated with the vaccine of the present invention but was not infected with *Sarcocystis neurona*.

Therefore, in a Western blot embodiment consisting of *Sarcocystis neurona* antigens resolved by gel electrophoresis, a biological sample from a vaccinated equid would contain antibodies that bind only with the 16 (\pm 4) antigen and 30 (\pm 4) kDa antigen whereas a sample from an equid infected with, or exposed to, *Sarcocystis neurona* would contain antibodies that bind with additional *Sarcocystis neurona* antigens. The equine antibodies that are bound are identified by treating the blot with labeled antibodies against equine antibodies. Preferably, the label is selected from the group consisting of alkaline phosphatase, horseradish peroxidase, fluorescent compounds, luminescent compounds, colloidal gold, and magnetic particles. Methods for preparing and analyzing Western blots are well known in the art. In a preferred embodiment, the Western blot is pretreated with non-equine antibodies against a *Sarcocystis* sp. other than *Sarcocystis neurona* wherein the pretreatment prevents binding of equine antibodies to those antigens common to all *Sarcocystis* spp. which can be present in the sample. This method is disclosed in Provisional Patent Application Serial No. 60/120,831, filed on February 19, 1999, which is hereby

incorporated herein by reference.

In an enzyme-linked immunosorbent assay (ELISA) embodiment, a microtiter plate is provided containing a plurality of wells wherein a first well or series of wells contains the 16 (\pm 4) kDa antigen immobilized to the surface therein, a second well or series of wells contains the 30 (\pm 4) kDa antigen immobilized to the surface therein, and a third well or series of wells contains another *Sarcocystis neurona* specific antigen immobilized to the surface therein. Next, the biological sample is added to the wells containing the bound antigens and antibodies against *Sarcocystis neurona* are allowed to bind to form an antibody-antigen complex. The biological sample can be provided neat or in a limiting dilution series in a physiological solution. Unbound material in the sample is removed from the antibody-antigen complex by washing. The complex is then reacted with a labeled antibody or labeled monoclonal antibody that binds to equine antibodies to form a second antibody-antigen complex. The second complex can be detected when the labeled monoclonal or polyclonal antibody is conjugated to a reporter ligand such as horseradish-peroxidase or alkaline phosphatase. Alternatively, the second monoclonal or polyclonal antibody can be conjugated to reporter ligands such as a fluorescing ligand, biotin, colored latex, colloidal gold magnetic beads, radioisotopes or the like. Detection of the complex is by methods well known in the art for detecting the particular reporter ligand. Therefore, a sample from an equid that had been vaccinated will produce antibodies against only the 16 (\pm 4) antigen and 30 (\pm 4) kDa antigen whereas a sample from an equid that is infected with, or exposed to, *Sarcocystis neurona* will contain antibodies against the third antigen in addition to containing

antibodies against the 16 (± 4) antigen and 30 (± 4) kDa antigen. ELISA was developed by Engvall et al., *Immunochem.* 8: 871 (1971) and further refined by others such as Ljunggren et al. *J. Immunol. Meth.* 104: 7-14 (1987) and Kemeny et al., *J. Immunol. Meth.* 87: 45-50 (1986). ELISA and its variations are well known in the art. The ELISA can be provided as a kit for distinguishing vaccinated equid from unvaccinated equid, and from an equine infected with *Sarcocystis neurona*.

Since it is important to be able to test samples in the field in order to distinguish equids infected with *Sarcocystis neurona* from equids vaccinated with the vaccine of the present invention, the present invention further includes rapid immunodiffusion-based methods, their devices, and kits comprising the same. Therefore, the present invention can be provided with a kit that comprises any one of the methods described in U.S. Patent No. 5,620,845 to Gould et al., U.S. patent No. 5,559,041 to Kang et al., U.S. Patent No. 5,656,448 to Kang et al., U.S. Patent No. 5,728,587 to Kang et al., U.S. Patent No. 5,695,928 to Stewart et al., U.S. Patent No. 5,169,789 to Bernstein et al. U.S. Patent No. 4,486,530 to David et al., and U.S. Patent No. 4,786,589 to Rounds et al. While the aforementioned disclose particular rapid immunodiffusion methods, the present invention is not to be construed to be limited to the aforementioned. It is within the scope of the present invention to embrace derivations and modifications of the aforementioned. For example, the 16 (± 4) antigen and/or 30 (± 4) kDa antigen are immobilized to one area of a membrane and a third *Sarcocystis neurona* antigen is immobilized to another area of the membrane in a device designed for analyzing a biological sample. A biological sample is applied to the membrane which

diffuses throughout the membrane. If the sample contains antibodies that form antibody-antigen complexes with all three antigens, the equid is infected with, or exposed to, *Sarcocystis neurona*. If the sample contains antibodies that form complexes with the 16 (± 4) and/or 30 (± 4) kDa antigens and no antibodies that bind to the third antigen, the equid has been vaccinated with the vaccine of the present invention but is not infected with *Sarcocystis neurona*. Detection of the antibody-antigen complex is by a colorimetric method incorporated into the device, by immersing the device into a solution that causes a colorimetric reaction, or by reacting with a labeled monoclonal or polyclonal antibody conjugated to a reporter ligand.

Another method for distinguishing vaccinated equids from equids infected with, or exposed to *Sarcocystis neurona* is to provide as the vaccine the aforementioned fusion polypeptide wherein the polypeptide comprises a marker epitope that elicits an antibody in the vaccinated equid that would not normally be present in the equid. For example, the marker epitope could be from a pathogen that does not infect equids or a synthetic polypeptide that elicits an antibody in equids that would not normally occur in equids. Therefore, if a sample from an equid contained antibodies against the marker epitope and the 16 (± 4) antigen and/or 30 (± 4) kDa antigen, the equid was vaccinated with the vaccine of the present invention, whereas if the sample does not contain antibodies against the marker epitope but does contain antibodies against the 16 (± 4) antigen and/or 30 (± 4) kDa antigen, the equid is infected with *Sarcocystis neurona*. The sample is tested according to any of the aforementioned diagnostic methods.

In a method further still for distinguishing

vaccinated equids from infected equids, the vaccine of the present invention consists of a polypeptide that comprises a subset of the total epitopes on the 16 (± 4) antigen and/or 30 (± 4) kDa antigen. Therefore, in an equid vaccinated with the above polypeptide vaccine, antibodies are produced against only those epitopes on the polypeptide whereas in an equid infected with *Sarcocystis neurona*, antibodies are produced against all of the epitopes. Thus, a sample from an infected equid will produce antibodies that binds the vaccine polypeptide and the full-sized antigen whereas a sample from a vaccinated equid will produce antibodies that will bind the vaccine polypeptide but not the full-sized antigen. The antibody-antigen or antibody-polypeptide complex can be detected by modifying any of the aforementioned diagnostic assays.

The following examples are intended to promote a further understanding of the present invention.

EXAMPLE 1

This example is to demonstrate the preparation of monoclonal antibodies that recognize 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

Sarcocystis neurona was cultured on equine dermal cell line cultures as taught in Example 3 or on bovine monocyte cell cultures as taught by Granstrom et al., J. Vet. Diagn. Invest. 5: 88-90 (1993). *Sarcocystis neurona* merozoites were harvested and the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen were purified by methods known to the art for purifying antigens, i.e., the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen were purified from merozoites by two-dimensional polyacrylamide gel electrophoresis. Then the purified antigens are used to make monoclonal

antibodies according to the methods in *Antibodies, A Laboratory Manual*, eds. Harlow and Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988), well known to those skilled in the art as a source for methods for making polyclonal and monoclonal antibodies.

BALB/c mice are immunized with an initial injection of 1.0 μ g of the 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen per mouse mixed 1:1 with Freund's complete adjuvant. After two weeks, a booster injection of 1.0 μ g of antigen is injected into each mouse intravenously without adjuvant. Three days after the booster injection the mouse serum is checked for antibodies to the 16 \pm 4 kDa and/or 30 \pm 4 kDa antigens. If positive, a fusion is performed with a mouse myeloma cell line. Mid log phase myeloma cells are harvested on the day of fusion, checked for viability, and separated from the culture medium by low-speed centrifugation. Then the cells are resuspended in serum-free Dulbecco's Modified Eagle's medium (DMEM).

The spleens are removed from the immunized mice and washed three times with serum-free DMEM and placed in a sterile Petri dish containing 20 ml of DMEM containing 20% fetal bovine serum, 1 mM pyruvate, 100 units penicillin, and 100 units streptomycin. The cells are released by perfusion with a 23 gauge needle. Afterwards, the cells are pelleted by low-speed centrifugation and the cell pellet is resuspended in 5 ml 0.17 M ammonium chloride and placed on ice for several minutes. Then 5 ml of 20% bovine fetal serum is added and the cells pelleted by low-speed centrifugation. Afterwards, the cells are resuspended in 10 ml DMEM and mixed with myeloma cells to give a ratio of 3:1. The cell mixture is pelleted by low-speed centrifugation, the supernatant fraction removed, and

the pellet allowed to stand for 5 minutes. Next, over a period of 1 minute, 1 ml of 50% polyethylene glycol (PEG) in 0.01 M HEPES pH 8.1 at 37°C is added. After 1 minute incubation at 37°C, 1 ml of DMEM is added for a period of another 1 minute, then a third addition of DMEM is added for a further period of 1 minute. Finally, 10 ml of DMEM is added over a period of 2 minutes. Afterwards, the cells are pelleted by low-speed centrifugation and the pellet resuspended in DMEM containing 20% fetal bovine serum, 0.016 mM thymidine, 0.1 hypoxanthine, 0.5 μ M aminopterin, and 10% hybridoma cloning factor (HAT medium). The cells are then plated into 96-well plates.

After 3, 5, and 7 days half the medium in the plates is removed and replaced with fresh HAT medium. After 11 days, the hybridoma cell supernatant is screened by an ELISA assay. In this assay, 96-well plates are coated with the appropriate 16 (\pm 4) kDa antigen or 30 (\pm 4) kDa antigen. One hundred μ l of supernatant from each well is added to a corresponding well on a screening plate and incubated for 1 hour at room temperature. After incubation, each well is washed three times with water and 100 μ l of a horseradish peroxidase conjugate of goat anti-mouse IgG (H+L), A, M (1:1,500 dilution) is added to each well and incubated for 1 hour at room temperature. Afterwards, the wells are washed three times with water and the substrate OPD/hydrogen peroxide is added and the reaction is allowed to proceed for about 15 minutes at room temperature. Then 100 μ l of 1 M HCl is added to stop the reaction and the absorbance of the wells is measured at 490 nm. Cultures that have an absorbance greater than the control wells are removed to 2 cm² culture dishes, with the addition of normal mouse spleen cells in HAT medium. After a further three days, the cultures

are rescreened as above and those that are positive are cloned by limiting dilution. The cells in each 2 cm² culture are counted and the cell concentration adjusted to 1 x 10⁵ cells per ml. The cells are diluted in complete medium and normal mouse spleen cells are added. The cells are plated in 96-well plates for each dilution. After 10 days, the cells are screened for growth. The growth positive wells are screened for antibody production; those testing positive are expanded to 2 cm² cultures and provided with normal mouse spleen cells. This cloning procedure is repeated until stable antibody producing hybridomas are obtained. Then the identified stable hybridomas are progressively expanded to larger culture dishes to provide stocks of the cells.

Production of ascites fluid is performed by injecting intraperitoneally 0.5 ml of pristane into female mice to prime the mice for ascites production. After 10 to 60 days, 4.5 x 10⁶ cells are injected intraperitoneally into each mouse and ascites fluid is harvested between 7 and 14 days later.

An alternate method for screening hybridomas for antibody production is as follows. *Sarcocystis neurona* is heat-denatured in 0.5 M Tris (pH 7.4) with 10% SDS, 20% glycerol and 5% 2-mercaptoethanol. The denatured antigens are separated by SDS-polyacrylamide gel electrophoresis in a 12-20% (v/v) linear gradient gel with a 4% (v/v) stacking gel. The separated antigens are electrophoretically transferred to Western PVDF membranes at 100 volts for 1.5 hours, then 150 volts for 0.5 hours. The membranes are then blocked overnight in 1% by volume bovine serum albumen in 0.5% Tween-Tris buffered saline (Blocking buffer). The blots are air-dried and stored frozen. Prior to use, the membranes are incubated with bovine serum albumin and *Sarcocystis cruzi* antibodies in Blocking buffer at a

range of 1:10 to 1:100 ratio for two hours. Afterwards, the membranes are washed in 0.5% Tween-Tris buffered saline and then incubated with monoclonal antibodies from the various hybridoma clones. The membranes are developed as disclosed in the prior art, e.g., Granstrom et al., J. Vet. Diag. Invest. 5: 88-90 (1993) or *Antibodies, A Laboratory Manual*, eds. Harlow and Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988).

Hybridomas that successfully produce monoclonal antibodies against various epitopes of the 16 (± 4) kDa antigen and 30 (± 4) kDa antigen are expanded as above, and used to make monoclonal antibodies for the antigen-based immunoassay and for identifying cDNA library clones in Example 2 that contain *Sarcocystis neurona* DNA which express either the 16 (± 4) and/or 30 (± 4) kDa antigens.

In the foregoing procedure, monoclonal antibodies against particular epitopes of the identifying antigens are produced.

EXAMPLE 2

This example shows the preparation of a cDNA library that expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*. The methods for making and screening cDNA expression libraries are well known to those skilled in the art and are described in *Molecular Cloning: A Laboratory Manual, Second Edition*, edited by Sambrook et al. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). The monoclonal antibodies made as in Example 1 are used to screen the library for clones that express the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen.

EXAMPLE 3

This example provides a simplified method for the isolation, excystation, and culture of *Sarcocystis* species using opossums as a model. The method is an improvement over the isolation, excystation and culture methods of the prior art and is useful for producing antigens from various *Sarcocystis neurona* strains for subunit vaccines, for making monoclonal and polyclonal antibody vaccines, and attenuated and killed whole organism vaccines.

Opossums are humanely killed and their intestines screened for *Sarcocystis* spp. oocysts. In addition, *Sarcocystis* oocysts collected from wild grackle (*Quiscalus* sp.) fed possums and oocysts collected from wild-caught cowbird (*Molothrus ater*) fed opossums in the inventors' laboratory can be used. A 2-cm segment of mid-small intestine from each animal is removed and washed with 0.01 M phosphate-buffered saline, pH 7.4 (PBS). A scraping of mucosa is observed at 100X magnification using a Nikon Optiphot-2 microscope to determine the presence or absence of oocysts. Feces from the large intestine is removed from each positive animal and tested for the presence of *Sarcocystis* spp. sporocysts and other parasite ova by sucrose flotation according to Sloss et al., In *Veterinary Clinical Parasitology*, Iowa State University Press, Ames, Iowa, (1994), p. 198. The small intestine is flushed with PBS to remove contents and slit lengthwise. The mucosa is scraped off with a glass slide and ground in a Dounce homogenizer. The slurry is transferred to a conical tube and washed three times with PBS by centrifugation for 10 minutes at 500 x g. The pellet is resuspended in 3 volumes of pepsin-NaCl-HCl (0.65% pepsin w/v, 0.86% NaCl w/v, 1% concentrated HCl v/v) and incubated at 37°C for 1.5 hours with frequent mixing. The slurry is washed 3 times with PBS

as above and the pellet stored in Hank's balanced salt solution (HBSS) plus penicillin (100 units/ml), amikacin (100 μ g/ml), and amphotericin B (1.25 μ g/ml) until further use. A 1 to 3 ml aliquot of the semidigested mucosa is concentrated by centrifugation for 10 minutes at 500 x g. The pellet is suspended in 15 ml of 2.6% sodium hypochlorite solution, stirred for 1.5 hours at room temperature, and washed once with PBS as above.

The improvement in the excystation and culture of *Sarcocystis* sp. over the prior art is the mechanical excystation step as set forth below. The washed sodium hypochlorite pellet is suspended in 15 ml 10% trypsin in alkaline chelating solution (ACS) which is a solution that consisted of 100 mM NaCl, 3 mM KCl, 9 mM Na₂HPO₄, 3 mM Na-citrate, 0.5 mM Na₂EDTA, 0.1% glucose, 0.3% HEPES, 100 units penicillin, and 1.25 μ g/ml amphotericin B, and incubated 1.5 hour at 37°C. After washing once with PBS as above, a drop of the pellet is compressed between sterile slides and shearing forces are applied by moving the slides back and forth. The material on the slides is washed with cell medium into flasks of confluent equine dermal cells (ATCC CCL-57, freely available from the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209) in Dulbecco's modified Eagle's medium (DMEM; available from GIBCO a division of Life Technologies, Bethesda, MD) plus L-glutamine, 6% heat-inactivated fetal bovine serum, penicillin (100 units/ml), amikacin (100 μ g/ml), and amphotericin B (1.25 μ g/ml). *Sarcocystis neurona* isolated from neural tissue of EPM-affected horses can be passaged continuously long term on this cell line. Before and after inoculation, equine dermal cells are grown at 37°C with 5% CO₂, with medium changed every other day for 7 days and weekly thereafter. After inoculation, cultures are observed weekly for evidence

of cellular damage due to *Sarcocystis* spp. replication and for the presence of extracellular merozoites using an Olympus CK2 inverted microscope. Positive cultures are confirmed by Romanowsky (modified Giemsa-Wright)-stained cytopsin of infected cells using a Shandon Cytospin 3 centrifuge and a Wescor 7100 Aerospray slide stainer. Separate sterile pipettes are used to add or withdraw media from each flask containing each separate strain to eliminate the possibility of cross contamination.

The above improved method enabled obtaining viable organisms from 7 opossums that had *Sarcocystis* sporocysts detected in the feces. All of these opossums were adult males, 6 of which were from the same Michigan farm on which two horses had been diagnosed with histopathologically confirmed EPM. Each opossum harbored a million or more oocysts in the small intestinal mucosa; however, fewer than two sporocysts per gram of feces were observed in each when feces from the large intestine was tested by sucrose flotation. Ascarid, strongyle, tapeworm, *Caillaria* sp., *Physaloptera* sp. eggs, or a combination of these eggs were also observed in the wild-caught animals.

In the improved method, processing the mucosa with a Dounce homogenizer and subsequent pepsin-NaCl-HCl digestion broke down tissues but did not disrupt *Sarcocystis* oocysts, many of which were still attached to tissue fragments (Murphy and Mansfield, 1999). Further digestion with sodium hypochlorite freed most of the oocysts and released many sporocysts. Three chemical excystation methods as set forth in Example 4 were attempted. All were effective in breaking down the oocyst walls and weakening the sporocyst walls, but none to few excysted sporocysts were detected afterward. However, mechanical excystation as performed according

to the improvement shown herein proved to be most effective, especially with the 10% trypsin ACS pretreated sporocysts.

5 Processed small intestine from the first
opossum isolate refrigerated in HBSS plus penicillin,
streptomycin, and amphotericin B remained contaminated
with bacteria. Inoculation of dermal cells with this
contaminated material resulted in cell death. Culture
and sensitivity testing proved the contaminating
10 organism to be *Alcalcigens* sp. Amikacin (100 μ g/ml) was
substituted for the streptomycin in the mucosal
preparation and in all subsequent solutions, including
the cell growth media. Amikacin killed the contaminant
and no bacterial contamination of any subsequent
15 isolates using the penicillin-amikacin-amphotericin B-
enhanced media.

Successful culture of merozoites from the first
opossum isolate occurred in 13 of 15 flasks into which
sporocysts pretreated with 10% trypsin in ACS and
20 mechanically excysted by the improved method herein were
inoculated. In contrast, 4 flasks each were inoculated
with the three different regimes of chemically excysted
sporocysts without mechanical excystation as shown in
Comparative Example 1. All remained negative except for
25 1 trypsin-ACS- and 1 bile-trypsin-pretreated inoculum.

Thus, the trypsin-ACS/mechanically excysted
sporocysts made as above, infected more efficiently than
those prepared by chemical methods; each flask became
positive by visual examination at about 10 to 30 sites
30 between about 5 to 15 days after inoculation. In
contrast, the trypsin-ACS pretreated sporocysts became
positive in culture 14 days after inoculation and at one
site, and the bile-trypsin-pretreated sporocysts became
positive in culture 26 days after inoculation at only
35 one site. Successful culture was further confirmed by

Romanowsky-stained cytospin of infected cells. All
flasks negative for merozoites visually and by
Romanowsky-stained cytospin of cells were discarded
eight weeks after inoculation because longer term
5 culture did not result in more positive flasks in
preliminary trials. The mechanical excystation method
has been used for all subsequent opossum isolates. The
six additional isolates became positive using microscope
visualization from 6 to 14 days after inoculation at
10 many sites in each flask. All strains isolated from
these seven opossums have grown well long term (six
months or longer).

Sporocysts collected from six specific
pathogen-free opossums fed wild-caught cowbird were
15 successfully excysted and grown in equine dermal cell
culture in our laboratory using this technique as were
sporocysts thought to be *Sarcocystis falcatula* from
opossums fed wild-caught grackle (these were wild-caught
opossums testing negative for *Sarcocystis* by fecal
20 flotation for three weeks prior to infection). The
cowbird isolates have grown well long term in equine
dermal cells. Marsh et al., J. Parasitology 83: 1189-
1192 (1997) have shown that an equine-derived
Sarcocystis neurona isolate grew highly efficiently long
25 term in equine dermal cells. The grackle-fed opossum
isolate grew in equine dermal cells but only for a brief
time, 3 to 8 weeks in three different infection trials.
Although the cell line was not effective for long-term
growth of this *Sarcocystis* sp., the excystation method
30 and initial culture were successful.

This example shows that multiple isolates of
merozoites have been successfully cultured from opossum-
derived *Sarcocystis* spp. oocysts using the improved
method of digestion followed by manual excystation.
35 Long-term growth of all opossum *Sarcocystis* spp. should

be possible using the improvement and the appropriate cell line. Equine dermal cells work well for *Sarcocystis neurona*, but other cell lines may be more useful for other *Sarcocystis* spp. A more complete understanding of the life cycle of *Sarcocystis neurona* and, therefore, of the factors that determine exposure of horses should be possible using the opossum isolates derived from the above improved excystation and culture methods.

EXAMPLE 4

This example provides three chemical excystation methods for preparing *Sarcocystis* sp. oocysts. The chemically prepared samples were compared to samples prepared by the improved method shown in Example 3.

Samples were prepared as in Example 3 except that after washing the pellet that had been suspended in 2.6% sodium hypochlorite, the samples were treated with either (1) 10% trypsin in ACS, (2) 10% bile and 2% trypsin in HBSS (Speer et al., J. Protozoology 33: 486-490 (1986)), or 5% sodium taurocholate and 2% trypsin in PBS (Speer et al., *ibid.*). All the samples were incubated at 37°C and 5% CO₂. The chemical methods provided poor results even though the methods were effective in breaking down the oocyst walls and weakening the sporocyst walls.

Flasks inoculated with samples from the three above chemically excysted sporocysts remained negative except for one trypsin-ACS- and one bile-trypsin-pretreated inoculum. The trypsin-ACS-pretreated sporocysts became positive in culture 14 days after inoculation in one site and the bile-trypsin-pretreated sporocysts became positive in culture 26 days after inoculation at one site. In contrast, the improved

5

10

-45-

WE CLAIM:

-1-

A vaccine for providing passive immunity to *Sarcocystis neurona* infection comprising antibodies which are against at least one epitope of a unique 16 (± 4) or 30 (± 4) antigen of *Sarcocystis neurona*.

-2-

The vaccine of Claim 1 wherein the antibodies are selected from the group consisting of polyclonal antibodies and monoclonal antibodies.

-3-

The vaccine of claim 1 wherein the vaccine is provided in a pharmaceutically accepted carrier.

-4-

A vaccine for active immunization of an equid against a *Sarcocystis neurona* infection comprising at least one epitope of a unique 16 (± 4) or 30 (± 4) antigen of *Sarcocystis neurona*.

-5-

The vaccine of Claim 4 wherein the antigen is a recombinant polypeptide produced in a plasmid in a microorganism other than *Sarcocystis neurona*.

-6-

The vaccine of Claim 5 wherein the microorganism is an *E. coli*.

-46-

-7-

The vaccine of Claim 6 wherein the antigen is a fusion polypeptide wherein an amino end or a carboxyl end of the antigen is fused to all or a portion of a polypeptide that facilitates isolation of the antigen from the microorganism in which the antigen is produced.

5

-8-

The vaccine of Claim 7 wherein the polypeptide is selected from the group consisting of glutathione S-transferase, protein A, maltose binding protein, and polyhistidine.

-9-

The vaccine of Claim 6 wherein the vaccine is provided in a pharmaceutically accepted carrier.

-10-

A vaccine for protecting an equid from a *Sarcocystis neurona* infection comprising a DNA that encodes at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

-11-

The vaccine of Claim 10 wherein the DNA is operably linked to a promoter to enable transcription of the DNA in a cell of an equid.

-12-

The vaccine of Claim 10 wherein the vaccine is provided in a pharmaceutically accepted carrier.

-47-

-13-

A method for vaccinating an equid against a *Sarcocystis neurona* infection comprising:

(a) providing a recombinant antigen of *Sarcocystis neurona* produced from a microorganism culture wherein the microorganism contains a DNA that encodes at least one epitope of a 16 (+4) kDa antigen and/or 30 (+4) kDa antigen of *Sarcocystis neurona*; and

(b) vaccinating the equid.

-14-

The method of Claim 13 wherein the recombinant antigen is in a pharmaceutically accepted carrier.

-15-

The method of Claim 13 wherein the recombinant antigen is a fusion polypeptide which is fused at the amino terminus or carboxyl terminus to a polypeptide that facilitates the isolation of the recombinant antigen.

-16-

The method of Claim 15 wherein the polypeptide includes all or a portion of the polypeptide selected from the group consisting of glutathione S-transferase, protein A, maltose binding protein, and polyhistidine.

-17-

The method of Claim 15 wherein the DNA is in a plasmid in a microorganism wherein the DNA is operably linked to a promoter which enables transcription of the DNA to produce the recombinant antigen for the vaccine.

-48-

-18-

A method for vaccinating an equid against a *Sarcocystis neurona* infection comprising:

(a) providing in a carrier solution a DNA in a plasmid which encodes at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*; and

(b) vaccinating the equid with the DNA in the carrier solution.

-19-

The method of Claim 18 wherein the carrier solution is a saline solution.

-20-

The method of Claim 18 wherein the DNA is operably linked to a promoter to enable transcription of the DNA in a cell of the equid.

-21-

A method for providing passive immunity to a *Sarcocystis neurona* infection in an equid comprising:

(a) providing antibodies against at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona* wherein the antibodies are selected from the group consisting of polyclonal antibodies and monoclonal antibodies; and

(b) inoculating the equid.

-22-

The method of Claim 21 wherein the antibodies are provided in a pharmaceutically accepted carrier.

-49-

-23-

A method for producing a polypeptide comprising:

5 (a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona* and a polypeptide that facilitates isolation of the fusion polypeptide;

10 (b) culturing the microorganism in a culture to produce the fusion polypeptide; and

(c) isolating the fusion polypeptide.

-24-

The method of Claim 23 wherein isolating the fusion polypeptide is by affinity chromatography.

-25-

The method of Claim 24 wherein the polypeptide is all or a portion of protein A and the affinity chromatography comprises an IgG-linked resin.

-26-

The method of Claim 24 wherein the polypeptide is polyhistidine and the affinity chromatography comprises a Ni^{2+} resin.

-27-

The method of Claim 24 wherein the polypeptide is glutathione S-transferase and the affinity chromatography comprises a glutathione Sepharose 4B resin.

-50-

-28-

The method of Claim 24 wherein the polypeptide is maltose binding protein and the affinity chromatography comprises an amylose resin.

-29-

A method for producing an antibody comprising:

(a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona* and a polypeptide that facilitates isolation of the fusion polypeptide;

(b) culturing the microorganism in a culture to produce the fusion polypeptide;

(c) isolating the fusion polypeptide;

(d) producing the antibody from the polypeptide.

-30-

A method for producing a monoclonal antibody comprising:

(a) providing a microorganism in a culture containing a DNA encoding a fusion polypeptide comprising at least one epitope of a 16 (\pm 4) kDa antigen and/or 30 (\pm 4) kDa antigen of *Sarcocystis neurona* and a polypeptide that facilitates isolation of the fusion polypeptide;

(b) culturing the microorganism in a culture to produce the fusion polypeptide;

(c) isolating the fusion polypeptide;

(d) producing the monoclonal antibody from the polypeptide.

-51-

-31-

The method of Claim 29 or 30 wherein isolating the fusion polypeptide is by affinity chromatography.

-32-

The method of Claim 31 wherein the polypeptide is all or a portion of protein A and the affinity chromatography comprises an IgG-linked resin.

-33-

The method of Claim 31 wherein the polypeptide is polyhistidine and the affinity chromatography comprises a Ni^{2+} resin.

-34-

The method of Claim 31 wherein the polypeptide is glutathione S-transferase and the affinity chromatography comprises a glutathione Sepharose 4B resin.

-35-

The method of Claim 31 wherein the polypeptide is maltose binding protein and the affinity chromatography comprises an amylose resin.

-36-

A monoclonal antibody that selectively binds to a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

-37-

An isolated recombinant protein encoded by a cDNA produced from RNA of *Sarcocystis neurona* encoding a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen.

-52-

-38-

An isolated DNA that encodes a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

-39-

A bacterial clone containing a plasmid comprising a DNA encoding a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

-40-

The bacterial clone of Claim 39 wherein the clone expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

-41-

A vaccine for an equid comprising an isolated recombinant protein encoded by a cDNA produced from mRNA of *Sarcocystis neurona* encoding a protein which is a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen, and a vaccine carrier.

5

-42-

A vaccine for an equid comprising a recombinant virus vector containing DNA encoding a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*, and a vaccine carrier.

-43-

The vaccine of Claim 42 wherein the recombinant virus is selected from the group consisting of equid herpesvirus, vaccinia virus, canary poxvirus, raccoon poxvirus, and adenovirus.

-53-

-44-

A DNA vaccine for an equid comprising a plasmid containing DNA encoding a 16 (± 4) and/or 30 (± 4) kDa protein of *Sarcocystis neurona*.

-45-

A method for protecting an equid against *Sarcocystis neurona* which comprises providing a vaccine that when injected into the equid causes the equid to produce antibodies against a 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of the *Sarcocystis neurona* wherein the antibodies prevent infection by the *Sarcocystis neurona*.

-46-

The method of Claim 45 wherein the vaccine comprises the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen in a vaccine carrier.

-47-

The method of Claim 45 wherein the vaccine is a recombinant virus vector that expresses the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen.

-48-

The method of Claim 47 wherein the recombinant virus vector is selected from the group consisting of equine herpesvirus, vaccinia virus, canary poxvirus, raccoon poxvirus, and adenovirus.

-49-

The method of Claim 45 wherein the vaccine comprises a DNA plasmid encoding the 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen.

-54-

-50-

5 The method of Claim 45 wherein the vaccine is
administered by a vaccination route selected from the
group consisting of intranasal administration,
intramuscular injection, intraperitoneal injection,
intradermal injection, and subcutaneous injection.

ABSTRACT

The present invention provides vaccines and methods for making the vaccines that actively or passively protect an equid or other animal against *Sarcocystis neurona*. In particular, the present invention provides vaccines that provide active immunity which comprise a polypeptide or DNA vaccine that contains or expresses at least one epitope of an antigen that has an amino acid sequence substantially similar to a unique 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*. The present invention further provides a vaccine that provides passive immunity to *Sarcocystis neurona* comprising polyclonal or monoclonal antibodies against at least one epitope of an antigen substantially similar to a unique 16 (± 4) kDa antigen and/or 30 (± 4) kDa antigen of *Sarcocystis neurona*.

COMBINED DECLARATION AND POWER OF ATTORNEY(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

(check one applicable item below)

☒ original.☐ design.

NOTE: With the exception of a supplemental oath or declaration submitted in a reissue, a supplemental oath or declaration is not treated as an amendment under 37 CFR 1.312 (Amendments after allowance). M.P.E.P. § 714.16, 7th Edition.

☐ supplemental.

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

☐ national stage of PCT.

NOTE: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P.

NOTE: See 37 C.F.R. § 1.63(d) (continued prosecution application) for use of a prior nonprovisional application declaration in the continuation or divisional application being filed on behalf of the same or fewer of the inventors named in the prior application.

☐ divisional.☐ continuation.

NOTE: Where an application discloses and claims subject matter not disclosed in the prior application, or a continuation or divisional application names an inventor not named in the prior application, a continuation-in-part application must be filed under 37 C.F.R. § 1.53(b) (application filing requirements — nonprovisional application).

☐ continuation-in-part (C-I-P).**INVENTORSHIP IDENTIFICATION**

WARNING: If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

VACCINE TO CONTROL EQUINE PROTOZOAL MYELOENCEPHALITIS
IN HORSES

(Declaration and Power of Attorney [1-1]—page 1 of 7)

SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b), or (c))

(a) ☒ is attached hereto.

NOTE: "The following combinations of information supplied in an oath or declaration filed on the application filing date with a specification are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(1) name of inventor(s), and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration on filing;

"(2) name of inventor(s), and attorney docket number which was on the specification as filed;
or

"(3) name of inventor(s), and title which was on the specification as filed."

Notice of July 13, 1995 (1177 O.G. 60).

(b) ☐ was filed on _____, as ☐ Serial No. 0 / _____
or ☐ _____
and was amended on _____ (if applicable).

NOTE: Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 C.F.R. § 1.67.

NOTE: "The following combinations of information supplied in an oath or declaration filed after the filing date are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(A) application number (consisting of the series code and the serial number, e.g., 08/123,456);

"(B) serial number and filing date;

"(C) attorney docket number which was on the specification as filed;

"(D) title which was on the specification as filed and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration; or

"(E) title which was on the specification as filed and accompanied by a cover letter accurately identifying the application for which it was intended by either the application number (consisting of the series code and the serial number, e.g., 08/123,456), or serial number and filing date. Absent any statement(s) to the contrary, it will be presumed that the application filed in the PTO is the application which the inventor(s) executed by signing the oath or declaration."

M.P.E.P. § 601.01(a), 7th Ed.

(c) ☐ was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____ (if any).

SUPPLEMENTAL DECLARATION (37 C.F.R. § 1.67(b))

(complete the following where a supplemental declaration is being submitted)

- ☐ I hereby declare that the subject matter of the
- ☐ attached amendment
 - ☐ amendment filed on _____

was part of my/our invention and was invented before the filing date of the original application, above-identified, for such invention.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

- ☒ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
- ☒ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 C.F.R. § 1.98.

PRIORITY CLAIM (35 U.S.C. §§ 119(a)–(d))

NOTE: "The claim to priority need be in no special form and may be made by the attorney or agent if the foreign application is referred to in the oath or declaration as required by § 1.63. The claim for priority and the certified copy of the foreign application specified in 35 U.S.C. 119(b) must be filed in the case of an interference (§ 1.630), when necessary to overcome the date of a reference relied upon by the examiner, when specifically required by the examiner, and in all other situations, before the patent is granted. If the claim for priority or the certified copy of the foreign application is filed after the date the issue fee is paid, it must be accompanied by a petition requesting entry and by the fee set forth in § 1.17(i). If the certified copy is not in the English language, a translation need not be filed except in the case of interference; or when necessary to overcome the date of a reference relied upon by the examiner; or when specifically required by the examiner, in which event an English language translation must be filed together with a statement that the translation of the certified copy is accurate." 37 C.F.R. § 1.55(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☒ no such applications have been filed.
- (e) ☐ such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

Ian C. McLeod - Registration No. 20,931

Mary M. Moyne - Registration No. 35,962

(check the following item, if applicable)

- ☒ I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.
- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

NOTE: "Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to ensure that communications from the Office are mailed to the current correspondence address. 37 CFR 1.63(d)(4)." § 601.03, M.P.E.P., 7th Edition.

SEND CORRESPONDENCE TO

☒ Address
McLEOD & MOYNE, P.C.
2190 Commons Parkway
Okemos, Michigan 48864

DIRECT TELEPHONE CALLS TO:
(Name and telephone number)

Ian C. McLeod
(517) 347-4100

☒ Customer Number 21036

(complete the following if applicable)

Since this filing is a ☐ continuation ☐ divisional there is attached hereto a Change of Correspondence Address so that there will be no question as to where the PTO should direct all correspondence.

(Declaration and Power of Attorney [1-1]—page 5 of 7)

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

NOTE: Each inventor must be identified by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and by his/her residence, post office address and country of citizenship. 37 CFR § 1.63(a)(3).

NOTE: Inventors may execute separate declarations/oaths provided each declaration/oath sets forth all the inventors. Section 1.63(a)(3) requires that a declaration/oath, inter alia, identify each inventor and prohibits the execution of separate declarations/oaths which each sets forth only the name of the executing inventor. 62 Fed. Reg. 53,131, 53,142, October 10, 1997,

Full name of sole or first inventor

Linda S. Mansfield
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)
Inventor's signature Linda S. Mansfield
Date 2/24/00 Country of Citizenship United States
Residence Bath, Michigan
Post Office Address 4849 Ballantine Road
Bath, Michigan 48808

Full name of second joint inventor, if any

Mary G. Rossano
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)
Inventor's signature Mary G. Rossano
Date 2/24/00 Country of Citizenship United States
Residence Mason, Michigan
Post Office Address 1588 Harper Road
Mason, Michigan 48854

Full name of third joint inventor, if any

Alice J. Murphy
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)
Inventor's signature Alice J. Murphy
Date 2/24/00 Country of Citizenship United States
Residence St. Johns, Michigan
Post Office Address 309 S. Oakland
St. Johns, Michigan 48879

(check proper box(es) for any of the following added page(s)
that form a part of this declaration)

☒ **Signature** for fourth and subsequent joint inventors. *Number of pages added*
1

* * *

☐ **Signature** by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. *Number of pages added* _____

* * *

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. *Number of pages added* _____

* * *

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)

* * *

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added _____

* * *

☐ Authorization of practitioner(s) to accept and follow instructions from representative.

* * *

(if no further pages form a part of this Declaration,
then end this Declaration with this page and check the following item)

☐ This declaration ends with this page.

**ADDED PAGE TO COMBINED DECLARATION AND POWER OF
ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS**

Full name of fourth joint inventor, if any

Ruth

A.

Vrable

GIVEN NAME

MIDDLE INITIAL OR NAME

FAMILY (OR LAST NAME)

Inventor's signature Ruth A. Vrable

Date Feb 24, 2000 Country of Citizenship United States

Residence Williamston, Michigan

Post Office Address 2585 Burkley Road
Williamston, Michigan 48895

Full name of fifth joint inventor, if any

GIVEN NAME

MIDDLE INITIAL OR NAME

FAMILY (OR LAST NAME)

Inventor's signature _____

Date _____ Country of Citizenship _____

Residence _____

Post Office Address _____

Full name of sixth joint inventor, if any

GIVEN NAME

MIDDLE INITIAL OR NAME

FAMILY (OR LAST NAME)

Inventor's signature _____

Date _____ Country of Citizenship _____

Residence _____

Post Office Address _____